Immunotech Laboratories, Inc. Announces Successful Completion of Phase III Testing of the Patented Immune Therapeutic Vaccine -1

MONROVIA, CA / ACCESSWIRE / January 25, 2017 / Immunotech Laboratories, Inc. (OTC PINK: IMMB – Greymarket) (the"Company" or "IMMB") announced today the completion of successful clinical Phase III testing on patients suffering from HIV/AIDS of its patented medical product, ITV-1-ImmunH treatment. The clinical trials were conducted through IMMB's subsidiary, Immunotech Laboratories BG – Europe ("IMMB-BG") at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases – "Prof. Ivan Kirov", Sofia Bulgaria. The trials, using the most current state of the art clinical testing methods available, which were approved at the World Practice Show, revealed significant positive results in treating the deadly disease. Data from the final report shows improvement in immune indices in the absolute number of LY, CD3 T, CD4 T, CD8 T, B Ly, NK levels and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and in the CD4/CD8 index. Most importantly, viral loads in approximately 80% of the blood samples of the patients, after completion of the treatment cycles, came back at non-detectable levels. Other important results noted in the summary report were the positive treatment effect on opportunistic infections, compatibility with all other antiviral drugs, high level of tolerance in all patients and the complete lack of any negative side effects.

The full report is available on the Company Website, www.immunotechlab.com. Additional information is available on the website of our subsidiary Immunotech Laboratories BG-Europe – www.immunh.com.

Immunotech Laboratories BG-Europe has filed for the permit for mass use, Phase IV, in Bulgaria and has reported to the Company that they believe the permit is forthcoming. As a result, IMMB has entered into a contract with Contract Manufacturing Organization ( CMO) located in California to produce the Immunotherapy Treatment as part of the approval process of the Bulgarian regulatory authority. In a coordinated effort to develop the project into a stable and longstanding enterprise Immunotech Laboratories, Inc. in conjunction with its subsidiary Immunotech Laboratories BG – Europe next step will be the completion of construction of a manufacturing facility in Bulgaria. This project began in the fourth quarter of 2017. Financing of the project has been secured by IMMB-BG. Additional information will be forthcoming in a separate press release.

The Company's laboratory, maintained in Monrovia California, continues research and development of additional applications of its patented immunotherapy treatments.

"Immunotech Laboratories, Inc. apologizes to its shareholders for the past actions which may have unintentionally caused the trust in the company to be impaired. The Company pursued every avenue available to have the temporary suspension resulting from the press release issued on October 20, 2014, retroactively lifted but to no avail. While this event caused the Company major delays in its pursuit of commercialization of its proprietary proteins for the treatment of debilitating infectious diseases, we are proud to say that our efforts have not been wasted. The results from the successful completion of the Phase III test on salvage patients under CRO oversight at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases exceeded our expectations," stated Harry H. Zhabilov CEO of IMMB and developer of the patented treatment.

Mr. Zhabilov further stated, "The Temporary Suspension expired on December 4, 2014 with the effect of moving the shares from the Pink Sheets to the Grey Sheets. No further action has been taken by any regulatory authorities since the expiration of the temporary suspension and the Company is now in the process of complying with the requirements to return the stock to a trading status."

About Immunotech:

Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.

Immunotech's flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.

While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests.

Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

IR Contact:

Harry Zhabilov
120 W Pomona Ave
Monrovia, CA 91016
Phone: (626) 538-4779
Fax: (626) 538-4779

SOURCE: Immunotech Laboratories, Inc.